| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0021 | 0.9 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.0032 | 1 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.003 | 1 |